Ultragenyx Pharmaceutical Inc
(NAS:RARE)
$
53.07
-0.75 (-1.39%)
Market Cap: 4.89 Bil
Enterprise Value: 4.23 Bil
PE Ratio: 0
PB Ratio: 11.32
GF Score: 75/100 Ultragenyx Pharmaceutical Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021 / 07:30PM GMT
Release Date Price:
$106.4
(-1.92%)
Tazeen Ahmad
BofA Securities, Research Division - VP
Good afternoon, everybody, and thanks for continuing to join us at the Bank of America Health Care Conference. My next presenter is Ultragenyx, which, of course, focuses on several rare diseases. So in the next 30 minutes, we will have a conversation on a number of topics in the pipeline.
And with me for this conversation will be Mardi Dier as well as Camille Bedrosian. Mardi and Camille, thanks for joining us. Good afternoon.
Mardi C. Dier
Ultragenyx Pharmaceutical Inc. - Executive VP & CFO
Yes, thanks for having us.
Camille L. Bedrosian
Ultragenyx Pharmaceutical Inc. - Chief Medical Officer & Executive VP
Thank you.
Questions & Answers
Tazeen Ahmad
BofA Securities, Research Division - VP
It is afternoon now in the West Coast to you. So maybe we can start off. You guys just reported the quarter recently. But for maybe the folks that are on who don't have as great of an understanding of
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |

30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot
